Skip to main content
Top
Published in: Arthritis Research & Therapy 1/2019

Open Access 01-12-2019 | Arthritis | Research article

Improved RA classification among early arthritis patients with the concordant presence of three RA autoantibodies: analysis in two early arthritis clinics

Authors: Cristina Regueiro, Lorena Rodríguez-Martínez, Laura Nuño, Ana M. Ortiz, Alejandro Villalba, Dora Pascual-Salcedo, Ana Martínez-Feito, Isidoro González-Alvaro, Alejandro Balsa, Antonio Gonzalez

Published in: Arthritis Research & Therapy | Issue 1/2019

Login to get access

Abstract

Background

The patients with RA benefit from early identification soon after the first clinical symptoms appear. The 2010 ACR/EULAR classification criteria were developed to fulfill this need and their application has been demonstrated to be effective. However, there is still room for improvement. Therefore, we aimed to evaluate the potential of the concordant presence of RF, anti-CCP and anti-carbamylated protein antibodies to improve current RA classification among early arthritis (EA) patients.

Methods

Data from the first visit of 1057 patients in two EA prospective cohorts were used. The serological scores from the 2010 ACR/EULAR criteria and the concordant presence of the three RA autoantibodies were assessed relative to a gold standard consisting of the RA classification with the 1987 ACR criteria at the 2 years of follow-up.

Results

The concordant presence of three antibodies showed predictive characteristics allowing for direct classification as RA (positive predictive value = 96.1% and OR = 80.9). They were significantly better than the corresponding to the high antibody titers defined as in the 2010 classification criteria (PPV = 88.8%, OR = 26.1). In addition, the concordant presence of two antibodies was also very informative (PPV = 82.3%, OR = 15.1). These results allowed devising a scoring system based only on antibody concordance that displayed similar overall performance as the serological scoring system of the 2010 criteria. However, the best classification was obtained combining the concordance and 2010 serological systems, a combination with a significant contribution from each of the two systems.

Discussion

The concordant presence of RA autoantibodies showed an independent contribution to the classification of EA patients that permitted increased discrimination and precision.
Literature
1.
go back to reference Smolen JS, Landewe R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960–77.CrossRef Smolen JS, Landewe R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960–77.CrossRef
2.
go back to reference Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European league against rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–81.CrossRef Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European league against rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–81.CrossRef
3.
go back to reference Radner H, Neogi T, Smolen JS, Aletaha D. Performance of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: a systematic literature review. Ann Rheum Dis. 2014;73(1):114–23.CrossRef Radner H, Neogi T, Smolen JS, Aletaha D. Performance of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: a systematic literature review. Ann Rheum Dis. 2014;73(1):114–23.CrossRef
4.
go back to reference Hua C, Daien CI, Combe B, Landewe R. Diagnosis, prognosis and classification of early arthritis: results of a systematic review informing the 2016 update of the EULAR recommendations for the management of early arthritis. RMD open. 2017;3(1):e000406.CrossRef Hua C, Daien CI, Combe B, Landewe R. Diagnosis, prognosis and classification of early arthritis: results of a systematic review informing the 2016 update of the EULAR recommendations for the management of early arthritis. RMD open. 2017;3(1):e000406.CrossRef
5.
go back to reference Juarez M, Bang H, Hammar F, Reimer U, Dyke B, Sahbudin I, Buckley CD, Fisher B, Filer A, Raza K. Identification of novel antiacetylated vimentin antibodies in patients with early inflammatory arthritis. Ann Rheum Dis. 2016;75(6):1099–107.CrossRef Juarez M, Bang H, Hammar F, Reimer U, Dyke B, Sahbudin I, Buckley CD, Fisher B, Filer A, Raza K. Identification of novel antiacetylated vimentin antibodies in patients with early inflammatory arthritis. Ann Rheum Dis. 2016;75(6):1099–107.CrossRef
6.
go back to reference Regueiro C, Nuno L, Ortiz AM, Peiteado D, Villalba A, Pascual-Salcedo D, Martinez-Feito A, Gonzalez-Alvaro I, Balsa A, Gonzalez A. Value of measuring anti-Carbamylated protein antibodies for classification on early arthritis patients. Sci Rep. 2017;7(1):12023.CrossRef Regueiro C, Nuno L, Ortiz AM, Peiteado D, Villalba A, Pascual-Salcedo D, Martinez-Feito A, Gonzalez-Alvaro I, Balsa A, Gonzalez A. Value of measuring anti-Carbamylated protein antibodies for classification on early arthritis patients. Sci Rep. 2017;7(1):12023.CrossRef
7.
go back to reference Boeters DM, Trouw LA, van der Helm-van Mil AHM, van Steenbergen HW. Does information on novel identified autoantibodies contribute to predicting the progression from undifferentiated arthritis to rheumatoid arthritis: a study on anti-CarP antibodies as an example. Arthritis Res Ther. 2018;20(1):94.CrossRef Boeters DM, Trouw LA, van der Helm-van Mil AHM, van Steenbergen HW. Does information on novel identified autoantibodies contribute to predicting the progression from undifferentiated arthritis to rheumatoid arthritis: a study on anti-CarP antibodies as an example. Arthritis Res Ther. 2018;20(1):94.CrossRef
8.
go back to reference Verheul MK, Bohringer S, van Delft MAM, Jones JD, Rigby WFC, Gan RW, Holers VM, Edison JD, Deane KD, Janssen KMJ, et al. Triple positivity for anti-Citrullinated protein autoantibodies, rheumatoid factor, and anti-Carbamylated protein antibodies conferring high specificity for rheumatoid arthritis: implications for very early identification of at-risk individuals. Arthritis Rheumatol. 2018;70(11):1721–31.CrossRef Verheul MK, Bohringer S, van Delft MAM, Jones JD, Rigby WFC, Gan RW, Holers VM, Edison JD, Deane KD, Janssen KMJ, et al. Triple positivity for anti-Citrullinated protein autoantibodies, rheumatoid factor, and anti-Carbamylated protein antibodies conferring high specificity for rheumatoid arthritis: implications for very early identification of at-risk individuals. Arthritis Rheumatol. 2018;70(11):1721–31.CrossRef
9.
go back to reference Gonzalez-Alvaro I, Ortiz AM, Alvaro-Gracia JM, Castaneda S, Diaz-Sanchez B, Carvajal I, Garcia-Vadillo JA, Humbria A, Lopez-Bote JP, Patino E, et al. Interleukin 15 levels in serum may predict a severe disease course in patients with early arthritis. PLoS One. 2011;6(12):e29492.CrossRef Gonzalez-Alvaro I, Ortiz AM, Alvaro-Gracia JM, Castaneda S, Diaz-Sanchez B, Carvajal I, Garcia-Vadillo JA, Humbria A, Lopez-Bote JP, Patino E, et al. Interleukin 15 levels in serum may predict a severe disease course in patients with early arthritis. PLoS One. 2011;6(12):e29492.CrossRef
10.
go back to reference Orozco G, Pascual-Salcedo D, Lopez-Nevot MA, Cobo T, Cabezon A, Martin-Mola E, Balsa A, Martin J. Auto-antibodies, HLA and PTPN22: susceptibility markers for rheumatoid arthritis. Rheumatology. 2008;47(2):138–41.CrossRef Orozco G, Pascual-Salcedo D, Lopez-Nevot MA, Cobo T, Cabezon A, Martin-Mola E, Balsa A, Martin J. Auto-antibodies, HLA and PTPN22: susceptibility markers for rheumatoid arthritis. Rheumatology. 2008;47(2):138–41.CrossRef
11.
go back to reference Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al. The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315–24.CrossRef Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al. The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315–24.CrossRef
12.
go back to reference Montes A, Regueiro C, Perez-Pampin E, Boveda MD, Gomez-Reino JJ, Gonzalez A. Anti-Carbamylated protein antibodies as a reproducible independent type of rheumatoid arthritis autoantibodies. PLoS One. 2016;11(8):e0161141.CrossRef Montes A, Regueiro C, Perez-Pampin E, Boveda MD, Gomez-Reino JJ, Gonzalez A. Anti-Carbamylated protein antibodies as a reproducible independent type of rheumatoid arthritis autoantibodies. PLoS One. 2016;11(8):e0161141.CrossRef
13.
go back to reference Shi J, Knevel R, Suwannalai P, van der Linden MP, Janssen GM, van Veelen PA, Levarht NE, van der Helm-van Mil AH, Cerami A, Huizinga TW, et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci U S A. 2011;108(42):17372–7.CrossRef Shi J, Knevel R, Suwannalai P, van der Linden MP, Janssen GM, van Veelen PA, Levarht NE, van der Helm-van Mil AH, Cerami A, Huizinga TW, et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci U S A. 2011;108(42):17372–7.CrossRef
14.
go back to reference Anderson DR, Burnham K. Model selection and multi-model inference: a practical information-theoretic approach. 2nd ed. New York: Springer-Verlag; 2004. Anderson DR, Burnham K. Model selection and multi-model inference: a practical information-theoretic approach. 2nd ed. New York: Springer-Verlag; 2004.
16.
go back to reference The jamovi project: jamovi. In., Version 0.9 edn; 2019: Computer software. The jamovi project: jamovi. In., Version 0.9 edn; 2019: Computer software.
17.
go back to reference Trouw LA, Mahler M. Closing the serological gap: promising novel biomarkers for the early diagnosis of rheumatoid arthritis. Autoimmun Rev. 2012;12(2):318–22.CrossRef Trouw LA, Mahler M. Closing the serological gap: promising novel biomarkers for the early diagnosis of rheumatoid arthritis. Autoimmun Rev. 2012;12(2):318–22.CrossRef
Metadata
Title
Improved RA classification among early arthritis patients with the concordant presence of three RA autoantibodies: analysis in two early arthritis clinics
Authors
Cristina Regueiro
Lorena Rodríguez-Martínez
Laura Nuño
Ana M. Ortiz
Alejandro Villalba
Dora Pascual-Salcedo
Ana Martínez-Feito
Isidoro González-Alvaro
Alejandro Balsa
Antonio Gonzalez
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 1/2019
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/s13075-019-2079-4

Other articles of this Issue 1/2019

Arthritis Research & Therapy 1/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.